Nanobiotix S.A. (NBTX) is in Healthcare, Biotechnology, based in France, listed on NasdaqGS. Market cap 1.17B USD. 52-week range 14.78 to 57.14 USD. Data as of 2026-10-09.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and ...